IDEXX Laboratories, Inc. is the global leader in veterinary diagnostics and practice management software, characterized by a defensive, recurring-revenue business model and a formidable economic moat. The company has successfully weathered post-pandemic macro volatility, maintaining sector-leading growth and profitability through robust price realization, product innovation, and strategic international expansion. Its unique position as an essential part of veterinary clinical workflows delivers high switching costs and strong resilience. However, investors face a valuation conundrum: IDEXX trades at a substantial premium, reflecting its rare competitive advantages but offering little room for operational missteps. This report delivers a comprehensive strategic, financial, and risk assessment, concluding that while IDEXX is a top-tier long-term compounder, caution is warranted due to premium pricing and sector headwinds.